LAM
NBIX icon

Lebenthal Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Lebenthal Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-395
Closed -$20K – 544
2016
Q3 		$20K Buy
+395
New +$19.7K ﹤0.01% 613

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lebenthal Asset Management's NBIX Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 395 shares — an estimated $20K sold.

Lebenthal Asset Management first reported a position in NBIX in Q3 2016 and held it in 1 quarter. The position peaked at $20K in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Lebenthal Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 395 Neurocrine Biosciences shares in Q4 2016, an estimated $20K.
  • Lebenthal Asset Management first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's Neurocrine Biosciences position peaked at $20K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.